Patent Grant
10384047
Transdermal and topical drug delivery can be used for therapeutic treatment, but the number of molecules that can be effectively delivered using these routes can be limited by the barrier properties of skin. The main barrier to transport of molecules through the skin is the stratum corneum (the outermost layer of the skin).
A number of different skin treatment methods have been proposed in order to increase the permeability or porosity of the outermost skin layers, such as the stratum corneum, thus enhancing drug delivery through or into those layers. The stratum corneum is a complex structure of compact keratinized cell remnants separated by lipid domains. The stratum corneum is formed of keratinocytes, which comprise the majority of epidermal cells that lose their nuclei and become corneocytes. These dead cells comprise the stratum corneum, which has a thickness of only about 10-30 microns and protects the body from invasion by exogenous substances and the outward migration of endogenous fluids and dissolved molecules. Various skin treatment methods include the use of microneedles, laser ablation, RF ablation, heat ablation, sonophoresis, iontophoresis, or a combination thereof.
Devices including arrays of relatively small structures, sometimes referred to as microneedles or micro-pins, have been disclosed for use in connection with the delivery of therapeutic agents and other substances through the skin and other surfaces. The devices are typically pressed against the skin in an effort to pierce the stratum corneum such that the therapeutic agents and other substances can sequentially or simultaneously pass through that layer and into the tissues below. Microneedles of these devices pierce the stratum corneum upon contact, making a plurality of microscopic slits which serve as passageways through which molecules of active components can be delivered into the body. In delivering an active component, the microneedle device can be provided with a reservoir for temporarily retaining an active component in liquid form prior to delivering the active component through the stratum corneum. In some constructions, the microneedles can be hollow to provide a liquid flow path directly from the reservoir and through the microneedles to enable delivery of the therapeutic substance through the skin. In alternate constructions, active component(s) may be coated on the microneedle array and delivered directly through the skin after the stratum corneum has been punctured.
Microneedle arrays can be used in conjunction with an applicator device capable of being used several times or as a single-use device. The microneedle arrays are generally used once and then discarded.
The present inventors recognized that issues related to applying microneedles include the ability to effectively and consistently insert the needles to a desired depth in the skin, the ability to reliably hold the microneedles in proper contact with the skin during the period of administration, and the ability to apply consistent force for delivery.
The present disclosure generally relates to articles comprising one or more hollow microneedles. In particular, the present disclosure provides a hollow microneedle with an opening that is configured to facilitate the delivery of material from the hollow microneedle into tissue (e.g., skin tissue). In addition, the present disclosure provides a method of making hollow microneedles.
Some aspects of the present disclosure provide an article. The article can comprise at least one hollow microneedle. The at least one microneedle can comprise a base, an elongated body having a central axis, a tip portion, a first channel, and a second channel. The tip portion can comprise a tip, a beveled surface, and a bevel opening in the beveled surface. The first channel can extend axially from the bevel opening through at least a portion of the elongated body, wherein the first channel has a first wall that is substantially aligned with the central axis. The second channel can extend radially from the first channel to the bevel opening, wherein the second channel has a second wall that is oriented substantially orthogonal to the central axis. The first channel and second channel merge to form the bevel opening.
Other aspects of the present disclosure provide a method of making an article comprising at least one microneedle. The microneedle can comprise an elongated body having body diameter, a base, a tip portion, and a hollow channel extending from the base to the tip portion. The method can comprise providing a first mold half comprising at least one cavity; wherein the at least one cavity includes a cavity opening and a cavity surface having a first projection extending therefrom toward the cavity opening; wherein the first projection defines a first segment of the hollow channel, the first segment extending into the body of the microneedle from the base; wherein the first projection comprises a first longitudinal axis. The method further can comprise providing a second mold half comprising at least one second projection extending therefrom; wherein the at least one second projection defines a tip portion of the microneedle and a second segment of the hollow channel, the second segment extending into the body of the microneedle from a bevel opening proximate the tip of the at least one microneedle; wherein the at least one second projection comprises a second longitudinal axis; wherein the second projection is shaped and dimensioned to define the tip portion; wherein the tip portion includes a tip, a beveled surface, a bevel opening in the bevel surface, a first channel that extends axially from the bevel opening through at least a portion of the elongated body, and a second channel that extends radially from the first channel to the bevel opening; wherein the first channel has a first wall that is substantially aligned with the second longitudinal axis; wherein the second channel has a second wall that is oriented substantially orthogonal to the second longitudinal axis; wherein the second projection is shaped and dimensioned such that the first channel and second channel merge to form the bevel opening. The method further can comprise contacting at least the first mold surface or the second mold surface with moldable material and inserting the second projection into the at least one cavity.
The phrase “injection apparatus” refers to an integrated device capable of delivering or extracting a fluid over a certain period and is not limited to devices intended solely for an infusion. Accordingly, an injection apparatus may be used, for example, for injecting fluid into the dermis or extracting fluid from tissue.
The term “transdermally” and variations thereof, is generally used to refer to any type of delivery of an active ingredient that crosses any portion of skin. That is, transdermally can generally include systemic delivery (i.e., where the active ingredient is transported across, or substantially through, the dermis such that the active ingredient is delivered into the bloodstream), as well as intradermal delivery (i.e., where the active ingredient is transported partially through the dermis, e.g., across the outer layer (stratum corneum) of the skin, where the active ingredient is delivered into the skin, e.g., for treating psoriasis or for local anesthetic delivery). That is, transdermal delivery as used herein includes delivery of an active ingredient that is transported across at least a portion of skin (but not necessarily all of the layers of skin), rather than merely being topically applied to an outer layer of the skin.
The phrase “hollow microneedle” refers to a specific microscopic structure that is designed for piercing the stratum corneum to facilitate the delivery of drugs through the skin. By way of example, microneedles can include needle or needle-like structures, as well as other structures capable of piercing the stratum corneum and delivering liquid drug formulations to skin or tissue layers beneath the stratum corneum.
The words “preferred” and “preferably” refer to embodiments of the invention that may afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the invention.
The terms “comprises” and variations thereof do not have a limiting meaning where these terms appear in the description and claims.
As used herein, “a,” “an,” “the,” “at least one,” and “one or more” are used interchangeably. Thus, for example, a microneedle can be interpreted to mean “one or more” microneedles.
The term “and/or” means one or all of the listed elements or a combination of any two or more of the listed elements.
Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.
Additional details of these and other embodiments are set forth in the accompanying drawings and the description below. Other features, objects and advantages will become apparent from the description and drawings, and from the claims.
The present invention will be further explained with reference to the drawing figures listed below, where like structure is referenced by like numerals throughout the several views.
Before any embodiments of the present disclosure are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the following drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. Unless specified or limited otherwise, the terms “mounted,” “connected,” “supported,” and “coupled” and variations thereof are used broadly and encompass both direct and indirect mountings, connections, supports, and couplings. It is to be understood that other embodiments may be utilized, and structural or logical changes may be made without departing from the scope of the present disclosure. Furthermore, terms such as “front,” “rear,” “top,” “bottom,” and the like are only used to describe elements as they relate to one another, but are in no way meant to recite specific orientations of the apparatus, to indicate or imply necessary or required orientations of the apparatus, or to specify how the invention described herein will be used, mounted, displayed, or positioned in use.
The present disclosure generally relates to articles comprising hollow microneedles having a tip portion that penetrates skin and provides an opening through which a composition (e.g., a pharmaceutically-active compound) can be delivered into the skin tissue and other tissue disposed in or underlying the skin tissue. In particular, the present disclosure relates to certain aspects of the tip portion that can provide more-efficient delivery of compositions into the skin tissue. In addition, the aspects generally provide a more-robust method of manufacturing hollow microneedles and particularly provide a more-robust method of manufacturing high-aspect-ratio hollow microneedles.
Articles comprising hollow microneedles and/or hollow microneedle arrays are used, for example, to deliver compositions (e.g., compositions comprising active ingredients). Such articles are described, for example, in U.S. Pat. Nos. 8,088,321 and 8,246,893; and U.S. Patent Application Publication Nos. US2011/0213335, US2012/0123387, US2012/0041337; and International Patent Publication No. WO2012/074576, which are all incorporated herein by reference in their entirety.
Turning to the drawings,
It will be recognized by a person having ordinary skill in the art that the body diameter 168 of the microneedle 160 may vary along the central axis 130 of the microneedle, depending upon the shape of the microneedle. The body diameter 168 shown in the illustrated embodiment corresponds to the diameter of the microneedle 160 at the base 162.
In contrast to the microneedle 160 of
Preferably, the angle of the bevel face 140 with respect to the central axis 130 is sufficiently acute such that it forms a sharp edge (e.g., for penetrating skin) at the tip 164. In the illustrated embodiment of
In any embodiment, the bevel face 140 has a pitch (i.e., angle in relation to the central axis of about 15° to about 40°. In a preferred embodiment, the bevel face 140 has a pitch of about 20° to about 35°. In a more preferred embodiment, the bevel face 140 has a pitch of about 25° to about 33°.
The microneedle 260 further comprises a hollow channel 170 that extends axially into the body 161 from the tip portion 166 from a bevel opening 172. The bevel opening 172 is defined by a first edge 174 of the face 140. The bevel face 140 is defined by a second edge 149. In any embodiment, no portion of the opening edge is coincident with any portion of the bevel edge (e.g., the opening may approximately centered within the area defined by the bevel face (not shown). Alternatively, in any embodiment, at least a portion of the first edge 174 is coincident with a portion of the second edge 149, as shown in
In any embodiment, the tip portion 166 of the microneedle 260 optionally comprises at least one secondary bevel 145. As shown in
The mold part 150′ further comprises a primary bevel-forming surface 153, secondary bevel-forming surfaces 155, and an extension 154′. The primary bevel-forming surface 153 defines the shape and angle, relative to the central axis, of the bevel face of the microneedle. The secondary bevel-forming surfaces 155 define the shape of the secondary bevels and the angle of the secondary bevels relative to the bevel face of the microneedle.
The extension 154′ defines the shape (e.g., circular) and size of the opening in the bevel face and also defines the shape (e.g., cylindrical) and diameter of the hollow channel in the microneedle. In any embodiment, the microneedle may comprise a hollow channel that extends only partially through the body of the microneedle (i.e., the hollow channel is a dead-end channel). In these embodiments, the extension 154′ may also define the depth of the hollow channel that is made using the mold part 150′. In any embodiment, an article according to the present disclosure may comprise hollow microneedles having a hollow channel that extends from one side of the article to another (e.g., to a reservoir located on the side opposite the microneedles, not shown).
In contrast to the mold part 150 of
In any embodiment, the bevel face of a microneedle according to the present disclosure defines a plane. In any embodiment, the plane is a flat plane. In any embodiment, the plane may be curved or slightly curved. In any embodiment, the bevel face may comprise a plurality of nonparallel planes (e.g. the bevel face may comprise a dihedral bevel face, as described in PCT Publication No. WO2015/009524, which is incorporated herein by reference in its entirety.
Hollow microneedles of the present disclosure can be made using molding processes that are known in the art. PCT Publication No. WO2014/099404, which is incorporated herein by reference in its entirety, for example describes the formation of microneedles using a molding process.
In another aspect, the present disclosure provides a method of making an article comprising at least one hollow microneedle that comprises a body having a central axis, a body diameter, a base, a tip portion, and a hollow channel. The method comprises providing a first mold half comprising at least one cavity. The at least one cavity includes a cavity opening and a cavity surface having a first projection extending therefrom toward the cavity opening. The first projection defines a first segment of the hollow channel, the first segment extending into the body of the microneedle from the base. The first projection comprises a first longitudinal axis. The method further comprises providing a second mold half comprising at least one second projection extending therefrom. The at least one second projection defines a tip portion of the at least one microneedle and a second segment of the hollow channel, the second segment extending into the body of the microneedle from a bevel opening proximate the tip of the at least one microneedle. The at least one second projection comprises a second longitudinal axis. The second projection is shaped and dimensioned to define the tip portion, as described herein. The method further comprises contacting at least the first mold half or the second mold half with moldable material (e.g., polymeric material, thermoplastic polymeric material), inserting the at least one second projection into the cavity opening so that the first projection is substantially aligned with the second projection, and forming the article. In any embodiment, after forming the article, the second projection causes the tip portion of the at least one microneedle to comprise a tip, a bevel face oriented diagonally with respect to the central axis and an opening that is formed by the merging of two channels that extend into the tip portion of the hollow microneedle. The first channel extends axially into the microneedle and the second channel extends radially, in an orientation that is substantially orthogonal to the central axis, from the first channel to the opening. In any embodiment, the second projection is inserted into the at least one cavity before contacting at least the first mold half or the second mold half with the moldable material. Alternatively, in any embodiment, at least the first mold half or the second mold half is contacted with the moldable material before inserting the second projection into the at least one cavity.
In any of the above embodiments of the method, the at least one cavity has a cavity aspect ratio (cavity length to cavity base width) of at least 1.5 to 1. In any of the above embodiments of the method, the first mold half comprises a plurality of the at least one cavities, wherein the second mold half comprises a plurality of the at least one second projections, wherein the plurality of second projections is aligned to be inserted simultaneously into the plurality of cavities.
Microneedle articles that are made according to the present disclosure can have a variety of configurations and features, such as those described in the following patents and patent applications, the disclosures of which are incorporated herein by reference in their entirety. One embodiment for the microneedle articles includes the structures disclosed in U.S. Pat. No. 6,312,612 (Sherman et al.), which describes tapered structures having a hollow central channel. Yet still another embodiment for the microneedle array articles includes the structures disclosed in U.S. Pat. No. 6,379,324 (Gartstein et al.), which describes hollow microneedles having at least one longitudinal blade at the top surface of the tip of the microneedle. A further embodiment for the microneedle array articles includes the structures disclosed in U.S. Patent Application Publication Nos. US2012/0123387 (Gonzalez et al.) and US2011/0213335 (Burton et al.), which both describe hollow microneedles. A still further embodiment for the microneedle array articles includes the structures disclosed in U.S. Pat. No. 6,558,361 (Yeshurun) and U.S. Pat. No. 7,648,484 (Yeshurun et al.), which both describe hollow microneedle arrays and methods of manufacturing thereof.
Various embodiments of features of microneedles that can be employed in the microneedle articles of the present disclosure are described in PCT Publication No. WO 2012/074576 (Duan et al.), which describes liquid crystalline polymer (LCP) microneedles; and PCT Publication No. WO 2012/122162 (Zhang et al.), which describes a variety of different types and compositions of microneedles that can be employed in the microneedles of the present disclosure.
Articles comprising hollow microneedles having features according to the present disclosure can be made, for example, by injection molding processes that are known in the art. In some embodiments, the microneedle material can be (or include) a metal, a ceramic, or a polymeric material, preferably a medical grade polymeric material. The microneedle material can be (or include) silicon or a metal such as stainless steel, titanium, or nickel titanium alloy. Exemplary types of medical grade polymeric materials include polycarbonate, liquid crystalline polymer (LCP), polyether ether ketone (PEEK), cyclic olefin copolymer (COC), polybutylene terephthalate (PBT). Preferred types of medical grade polymeric materials include polycarbonate and LCP.
The microneedle articles of the present disclosure can be manufactured in any suitable way such as by injection molding, compression molding, metal injection molding, stamping, photolithography, or extrusion. In any embodiment, hollow microneedle arrays can be made by injection molding of a polymer such as medical grade polycarbonate or LCP, followed by laser drilling to form the channels of the hollow microneedles. Nonlimiting examples of molding processes for molding polymeric materials into solid microneedle articles can be found in U.S. Pat. No. 8,088,321 (Ferguson et al.) and U.S. Patent Application Publication Nos. 2012/0258284 (Rendon) and 2012/0041337 (Ferguson et al.), each of which is incorporated herein by reference in its entirety. A non-limiting example of a publication that discloses the formation of hollow channels in articles comprising microneedles is PCT Publication No. WO2014/105458, which is incorporated herein by reference in its entirety.
In some embodiments, the microneedle material can be (or include) a biodegradable polymeric material, preferably a medical grade biodegradable polymeric material. Exemplary types of medical grade biodegradable materials include polylactic acid (PLA), polyglycolic acid (PGA), PGA and PLA copolymer, polyester-amide polymer (PEA).
In some embodiments, the hollow microneedles can be a prepared from a dissolvable, degradable, or disintegradable material referred to herein as “dissolvable microneedles”. A dissolvable, degradable, or disintegradable material is any solid material that dissolves, degrades, or disintegrates during use. In particular, a “dissolvable microneedle” dissolves, degrades, or disintegrates sufficiently in the tissue underlying the stratum corneum to allow a therapeutic agent to be released into the tissue. The therapeutic agent may be coated on or incorporated into a dissolvable microneedle. In some embodiments, the dissolvable material is selected from a carbohydrate or a sugar. In some embodiments, the dissolvable material is polyvinyl pyrrolidone (PVP). In some embodiments, the dissolvable material is selected from the group consisting of hyaluronic acid, carboxymethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinyl alcohol, sucrose, glucose, dextran, trehalose, maltodextrin, and a combination thereof.
In any embodiment, the hollow microneedles can be made from (or include) a combination of two or more of any of the above mentioned materials. For example, the tip of a microneedle may be a dissolvable material, while the remainder of the microneedle is a medical grade polymeric material.
A microneedle or the plurality of hollow microneedles in a microneedle-containing article of the present disclosure can have a variety of shapes that are capable of piercing the stratum corneum. In some of the embodiments, one or more of the plurality of microneedles can have a square pyramidal shape, triangular pyramidal shape, stepped pyramidal shape, conical shape, microblade shape, or the shape of a hypodermic needle. In any embodiment, one or more of the plurality of microneedles can have a square pyramidal shape. In any embodiment, one or more of the plurality of microneedles can have a triangular pyramidal shape. In any embodiment, one or more of the plurality of microneedles can have a stepped pyramidal shape. In any embodiment, one or more of the plurality of microneedles can have a conical shape. In any embodiment, one or more of the plurality of microneedles can have the shape of a hypodermic needle. In any embodiment, a microneedle array article may comprise an array of microneedles having a combination of any two or more of the foregoing microneedle shapes. The shape of any microneedle in the microneedle array article can be symmetric or asymmetric. The shape of any microneedle in the microneedle array article can be truncated (for example, the plurality of microneedles can have a truncated pyramid shape or truncated cone shape). In a preferred embodiment, each microneedle of the plurality of microneedles in a microneedle array article has a square pyramidal shape.
In any embodiment, each microneedle of the plurality of microneedles in a microneedle array article is a hollow microneedle (that is, the microneedle contains a hollow bore through the microneedle). The hollow bore can be from the base of the microneedle to the tip of the microneedle or the bore can be from the base of the microneedle to a position offset from the tip of the microneedle. In any embodiment, one or more of the plurality of hollow microneedles in a hollow microneedle array can have a conical shape, a cylindrical shape, a square pyramidal shape, a triangular pyramidal shape, or the shape of a hypodermic needle.
In any embodiment, one or more microneedle of the plurality of hollow microneedles in a hollow microneedle array article can have a conical shape; optionally, with a radius of curvature. In any embodiment, one or more microneedle of the plurality of hollow microneedles in a hollow microneedle array article can have a cylindrical shape. In any embodiment, one or more microneedle of the plurality of hollow microneedles in a hollow microneedle array article can have a segment having a square pyramidal shape. In any embodiment, one or more microneedle of the plurality of hollow microneedles in a hollow microneedle array article can have a segment having a triangular pyramidal shape. In any embodiment, one or more microneedle of the plurality of hollow microneedles in a hollow microneedle array article can have a segment having the shape of a hypodermic needle. In a preferred embodiment, each microneedle of the plurality of hollow microneedles in a hollow microneedle array article has a segment with the shape of a conventional hypodermic needle.
In any embodiment, an article comprising a hollow microneedle according to the present disclosure may comprise a plurality of the microneedles. The plurality of the microneedles optionally may form an array. In any embodiment, the article can comprise an array of about 3 to about 30, inclusive, of the hollow microneedles of the present disclosure. In a preferred embodiment, the article can comprise an array of about 8 to about 20, inclusive, of the hollow microneedles of the present disclosure. In a more-preferred embodiment, the article can comprise an array of 12, 16, or 18 of the hollow microneedles of the present disclosure.
In any embodiment of an article comprising a plurality of hollow microneedles according to the present disclosure, the overall height of each microneedle is about 400 μm to about 3000 μm. In any embodiment of an article comprising a plurality of hollow microneedles according to the present disclosure, the overall height of each microneedle is about 400 μm to about 2000 μm. In any embodiment of an article comprising a plurality of hollow microneedles according to the present disclosure, the overall height of each microneedle is about 750 μm to about 1600 μm.
In any embodiment of an article comprising a plurality of hollow microneedles according to the present disclosure, a hollow channel extending through each of the microneedles has a diameter, proximate the tip of the microneedle, of about 10 μm to about 200 μm. In any embodiment of an article comprising a plurality of hollow microneedles according to the present disclosure, a hollow channel extending through each of the microneedles has a diameter, proximate the tip of the microneedle, of about 10 μm to about 120 μm. In any embodiment of an article comprising a plurality of hollow microneedles according to the present disclosure, a hollow channel extending through each of the microneedles has a diameter, proximate the tip of the microneedle, of about 25 μm to about 75 μm.
In any embodiment of an article comprising a plurality of hollow microneedles according to the present disclosure, a hollow channel extending through each of the microneedles has a cross-sectional area of about 75 μm2 to about 32,000 μm2. In any embodiment of an article comprising a plurality of hollow microneedles according to the present disclosure, a hollow channel extending through each of the microneedles has a cross-sectional area of about 75 μm2 to about 18,000 μm2. In any embodiment of an article comprising a plurality of hollow microneedles according to the present disclosure, a hollow channel extending through each of the microneedles has a cross-sectional area of about 700 μm2 to about 3,000 μm2.
The hollow microneedle array articles of the present disclosure can be manufactured by injection molding of a polymer such as medical grade polycarbonate or LCP. Typically, these processes use molds to form the substrate with the microneedles extending therefrom.
Microneedles of the present disclosure advantageously provide a larger opening, with respect to a predetermined microneedle wall thickness, than can be attained using conventional process known in the art. The larger opening facilitates the delivery of material (e.g., pharmaceutically-active compositions) from the hollow channel of the microneedle into the skin tissue and underlying layers of tissue.
In addition, using a process according to the present disclosure, the microscopic mold parts that are used to form the tip portion of the needle are significantly less susceptible to damage during extended use because the extensions that form the tip-proximal hollow channel in the microneedle are made stronger by the presence of the protrusion that forms the second bevel face.
Any of the above embodiments of a microneedle according to the present disclosure can be used for injecting fluid into a body. Any of the above embodiments of a microneedle according to the present disclosure can be used for extracting fluid from a body.
Embodiment A is an article, comprising:
at least one microneedle, the at least one microneedle comprising:
Embodiment B is the article of Embodiment A, wherein the article further comprises a substrate having a first side and a second side, wherein the at least one microneedle extends from the first side of the substrate, wherein the first channel extends from the bevel opening through the elongated body to a second opening on the second side of the substrate.
Embodiment C is the article of Embodiment A or Embodiment B, wherein the at least one microneedle comprises a plurality of microneedles.
Embodiment D is the article of any one of the preceding Embodiments, wherein the bevel opening is an elongated opening comprising a first end proximate the tip and a second end proximate the base.
Embodiment E is the article of any one of Embodiments A through D, wherein the beveled surface is defined by a bevel edge surrounding the beveled surface, wherein the opening is defined by an opening edge surrounding the opening, wherein no portion of the opening edge is coincident with any portion of the bevel edge.
Embodiment F is the article of any one of Embodiments A through D, wherein the beveled surface is defined by a bevel edge surrounding the beveled surface, wherein the opening is defined by an opening edge surrounding the opening, wherein at least a portion of the opening edge is coincident with a portion of the bevel edge.
Embodiment G is the article of any one of the preceding Embodiments, wherein the tip portion comprises plurality of intersecting planes.
Embodiment H is the article of any one of the preceding Embodiments, wherein the bevel face defines a first plane, wherein a first two-dimensional area defined by the bevel opening is larger than a second two-dimensional area defined by a cross-sectional area of the first channel taken along the first plane.
Embodiment I is a use of the article of any one of Embodiments A through H for injecting fluid into a body.
Embodiment J is a use of the article of any one of Embodiments A through H for removing fluid from a body.
Embodiment K is a method of making an article comprising at least one microneedle that comprises an elongated body having body diameter, a base, a tip portion, and a hollow channel extending from the base to the tip portion; the method comprising:
Embodiment L is the method of Embodiment K, wherein the second projection is inserted into the at least one cavity before contacting at least the first mold surface or the second mold surface with the moldable material.
Embodiment M is the method of Embodiment K, wherein at least the first mold surface or the second mold surface is contacted with the moldable material before inserting the second projection into the at least one cavity.
Embodiment N is the method of any one of Embodiments K through M, wherein the moldable material comprises a metal, a ceramic material, or a polymeric material.
Embodiment O is the method of any one of Embodiments K through N, wherein the at least one cavity has a cavity aspect ratio (cavity length to cavity base width) of at least 1.5 to 1.
Embodiment P is the method of any one of Embodiments K through), wherein the first mold half comprises a plurality of the at least one cavities, wherein the second mold half comprises a plurality of the at least one second projections, wherein the plurality of second projections is aligned to be inserted simultaneously into the plurality of cavities.
The microneedle articles were prepared from polymeric material using standard injection molding procedures. The molded microneedle articles were prepared using a mold assembly prepared from three mold sections with each section machined from steel. The first mold section contained projections that defined the beveled shape of the needle tip in the molded array. Each projection in the first mold section had a further cylindrical extension that defined features of the tip segment of the microneedles tip, including the opening on a bevel proximate the tip of the microneedle and a portion of the hollow channel extending through the body of each microneedle. The second mold section served as a template to define the pattern of the microneedles in the molded article, the external shape and size of the microneedles in the molded article, and the first side of the article (including the central cavity portion, platform portion, and peripheral portion, as described above). The third mold section contained cylindrical projections emerging from a planar surface with each projection defining a second (base-proximal) part of the microneedle hollow channel and the opening located at the base of each microneedle in the molded article. The planar surface from which the projections emerged served to define the second major surface of the base segment of the molded article. The first and second mold sections were assembled to form a tight fit by inserting the projections of the first mold section into the corresponding openings in the second mold section. The assembled first and second mold sections formed the first mold half. The third mold section was used as the second mold half.
The first and second mold halves were installed in a mold base in a 60-ton injection molding press (Sodick Plustech LA 60, Sodick Plustech Co., Yokohama, Japan). As is common in the art, the parting line of the mold assembly had both primary and secondary vents for general air evacuation during injection of the polymeric material. Vectra MT1300 liquid crystal polymer (LCP) pellets (Ticona Engineering Polymers, Florence, Ky.) were loaded into a reciprocating screw and heated until molten. The first mold half and second mold half were heated to a temperature (hereafter referred to as the “mold temperature at injection”) of 200° F. (93.3° C.). The molding cycle was initiated by closing the first mold half with the second mold half. The molds were clamped together with approximately 20 to 60 tons of force. In the clamped position, the surfaces at the tips of the projections in the second mold half were aligned with and in contact with the surfaces at the tips of the projections in the first mold half. A first portion (approx. 50-95% of the part size volume) of the total amount of material from the reciprocating screw was injected into the mold chamber at a fixed velocity (hereafter referred to as the “injection velocity”) of about 7 inches/second (17.8 cm/second). After injecting the first portion of material, the process was switched from an injection-driven to a pressure-driven mode by applying a fixed pressure (hereafter referred to as the “pack pressure”) of about 13,500 psi (93,079 kilopascal) to force the remainder of the molten material into the negative mold insert. The pack pressure was applied for a fixed time (hereafter referred to as the “hold time”) of 5 seconds. The pack pressure was subsequently released and the mold chamber was cooled to an ejection temperature set below the softening temperature of LCP. The mold chamber was opened and the microneedle article was ejected.
Fully assembled microneedle article injection apparatuses similar to apparatuses described in U.S. Patent Application Publication No. US2012/0123387 (FIGS. 1-13) and PCT Publication No. WO2014/099404 (FIGS. 2, 14 and 15) were used. The drug cartridge in each apparatus contained al mL solution of 0.005% methylene blue in five percent aqueous dextrose. The injection apparatus from Example 1 of PCT Publication No. WO2014/009404 was used with the following exceptions. First, the section of the apparatus joined to the adhesive assembly was not milled to remove material. Second, the construction of the adhesive assembly was different. Instead of using the four layer adhesive of PCT Publication No. WO2014/099404, the adhesive assembly used was a laminate composed of only two layers. The first layer was a 0.10 mm thick sheet of 3M 1510 double sided tape (available from the 3M Company). The second layer was a 0.07 mm sheet of 3M 1524 transfer adhesive. The two layer adhesive assembly was positioned to cover the first major surface of base member of the lower housing at the rounded end section of the device. The adhesive assembly laminate was laser cut so that the size and shape of the adhesive assembly was matched to that of the device. The two layers of the adhesive assembly each contained cut-out regions that were aligned to each other and exactly matched the opening in the device housing. The device and adhesive assembly were oriented so that the first layer of the adhesive assembly was adhered to the lower housing of the device. The adhesive assembly was aligned with the device so that the opening in the first layer of the adhesive assembly was coincident with the opening in the device. A release liner was used during storage of the device to protect the exposed adhesive of the second layer of the adhesive assembly.
The hollow microneedle article used in the microneedle article injection apparatus (as shown in
The same microneedle injection apparatus as described in Example 2 was used with the exception that the wire diameter of the U-shaped leaf-like insertion spring (i.e. first stored energy device as described in U.S. Patent Application Publication No. US2012/0123387 (FIGS. 1-13) and PCT Publication No. WO2014/099404 (FIGS. 2, 14 and 15)) was 1.50 mm instead of 1.59 mm.
The same microneedle injection apparatus as described in Example 2 was used with the exception that the wire diameter of the U-shaped leaf-like insertion spring (i.e. first stored energy device as described in U.S. Patent Application Publication No. US2012/0123387 (FIGS. 1-13) and PCT Publication No. WO2014/099404 (FIGS. 2, 14 and 15)) was 1.40 mm instead of 1.59 mm.
The study was conducted using Yorkshire cross domestic pigs (Midwest Research Swine, Gibbon, Minn.) in vivo. A soft region of the belly having minimal muscle content was selected as the application site for microneedle insertion. The application site was first trimmed with an electric clipper and then shaved using a razor and shaving cream. The shaved area was scrubbed using soapy water and a BUF-PUF exfoliation sponge (3M Company, St. Paul, Minn.) and then rinsed with deionized water. The animal was placed in a lateral recumbent position on a heated table (38° C.). The animal was anesthetized with isofluorene gas and maintained under anesthesia throughout the experiment. The application site was then wiped with a 70% isopropanol in water solution.
The injection apparatus of Example 4 was used. The release liner was removed from the adhesive assembly and the apparatus was adhered to the skin of the pig. During attachment of the device to the pig, the skin at the application site was gently stretched to provide a slight tension to the skin. The skin was then allowed to relax and the push-button was depressed to cause release of the applicator element and insertion of the microneedle article into the skin of the pig. Removal of the tapered pin from the housing released the coiled spring which initiated the injection of the methylene blue solution into the pig. After completion of the injection, the apparatus was maintained on the skin for one additional minute. The apparatus was removed from the skin and the skin surface was examined to determine if there was any methylene blue solution on the surface of the skin. The presence of methylene blue solution on the skin was an indication that not all of the methylene blue was injected into the animal. The injection site was wiped with a pre-tared absorbent wipe and the wipe was then weighed to determine the amount of methylene blue that was not successfully delivered.
A total of three replicates were conducted. The injection times ranged from 29 to 111 seconds with the average injection time being 63 seconds. Two of the apparatuses successfully delivered the methylene blue solution without any “leakage” (i.e. no methylene blue solution was observed on the skin surface). The third apparatus successfully delivered 97% of the methylene blue solution.
A study was conducted to determine the depth of penetration (DOP) of the microneedles of the article when applied to the skin surface of a Yorkshire cross domestic pigs (Midwest Research Swine), in vivo. The hollow microneedle article described in Example 2 was used.
The microneedles on the article were coated using a three step process. The first two steps involved applying primer coatings to the microneedles and the third step involved applying a thin coating of Rhodamine B to the microneedles. In Step 1, the articles were flood coated with a 35 microliter solution containing 0.5 mg/mL polyvinyl alcohol (80% hydrolyzed) (Sigma-Aldrich, Inc., St. Louis, Mo.) and 35 μg/ml of TWEEN® 80 (Sigma-Aldrich) in 90% (w/v) ethanol. The coated articles were then dried at 35° C. for 20 minutes. In Step 2, the articles from Step 1 were flood coated with 35 microliters of an aqueous solution of 33.3 mg/ml aluminum potassium sulfate (Penta Manufacturing, Livingston, N.J.). The coated articles were then dried at 35° C. for 30 minutes. In Step 3, the primed articles from Step 2 were flood coated with 40 microliters of an aqueous solution of 0.08% (w/v) Rhodamine B (Sigma-Aldrich). The coated articles were dried at 35° C. for 30 minutes. The three step process provided articles in which the microneedles were completely covered with a thin, opaque coating of Rhodamine B.
The ham region was selected as the application site for microneedle insertion. The application site was first trimmed with an electric clipper and then shaved using a razor and shaving cream. The shaved area was scrubbed using soapy water and a BUF-PUF exfoliation sponge (3M Company) and then rinsed with deionized water. The animal was placed in a lateral recumbent position on a heated table (38° C.). The animal was anesthetized with isofluorene gas and maintained under anesthesia throughout the experiment. The application site was then wiped with a 70% isopropanol in water solution.
The injection apparatus described in Example 2 with a Rhodamine B coated article was used. The release liner was removed from the adhesive assembly and the apparatus was adhered to the skin of the pig. The push-button was depressed to cause release of the applicator element and insertion of the microneedles of the microneedle article into the skin of the pig. The injection apparatus was maintained on the skin for an additional 5 minutes.
The injection apparatus was removed from the animal. The depth of penetration (DOP) of the microneedles into the pig skin was determined indirectly by measuring the distance from the tip of the microneedle to where the Rhodamine B coating was wiped or dissolved from the microneedle after application into the skin. The measurement was conducted using a Nikon LV-100 microscope at 100× magnification (Nikon Instruments, Melville, N.Y.) with Image Pro® Plus digital image analysis software (Media Cybernetics, Bethesda, Md.). A total of two replicates were conducted. The mean microneedle DOP was determined by sampling all of the microneedles from each article (n=24). The results are presented in Table 1.
The procedure as described in Example 6 was used with the exception that the injection apparatus of Example 3 was used instead of the injection apparatus of Example 2. The results are presented in Table 2.
Use of Microneedle Article
The procedure as described in Example 6 was used with the exception that the injection apparatus of Example 4 was used instead of the injection apparatus of Example 2. The results are presented in Table 3.
The complete disclosure of all patents, patent applications, and publications, and electronically available material cited herein are incorporated by reference. In the event that any inconsistency exists between the disclosure of the present application and the disclosure(s) of any document incorporated herein by reference, the disclosure of the present application shall govern. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.
All headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless so specified.
Various modifications may be made without departing from the spirit and scope of the invention. These and other embodiments are within the scope of the following claims.
This application is a national stage filing under 35 U.S.C. 371 of PCT/US2014/046097, filed Jul. 10, 2014, which claims priority to U.S. Provisional Patent Application No. 61/846,945, filed Jul. 16, 2013, the disclosure of which is incorporated by reference in its entirety herein.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2014/046097 | 7/10/2014 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2015/009523 | 1/22/2015 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3308822 | De Luca | Mar 1967 | A |
| 4490139 | Huizenga et al. | Dec 1984 | A |
| 5575780 | Saito | Nov 1996 | A |
| 5752942 | Doyle et al. | May 1998 | A |
| 6091975 | Daddona et al. | Jul 2000 | A |
| 6312612 | Sherman et al. | Nov 2001 | B1 |
| 6379324 | Gartstein et al. | Apr 2002 | B1 |
| 6451240 | Sherman et al. | Sep 2002 | B1 |
| 6471903 | Sherman et al. | Oct 2002 | B2 |
| 6517523 | Kaneko et al. | Feb 2003 | B1 |
| 6558361 | Yeshurun | May 2003 | B1 |
| 6824378 | King et al. | Nov 2004 | B2 |
| 7070583 | Higuchi et al. | Jul 2006 | B1 |
| 7648484 | Yeshurun et al. | Jan 2010 | B2 |
| 8088321 | Ferguson et al. | Jan 2012 | B2 |
| 8246893 | Ferguson et al. | Aug 2012 | B2 |
| 20050049549 | Wong | Mar 2005 | A1 |
| 20050065463 | Tobinaga et al. | Mar 2005 | A1 |
| 20050261631 | Clarke et al. | Nov 2005 | A1 |
| 20060202385 | Xu et al. | Sep 2006 | A1 |
| 20070078376 | Smith | Apr 2007 | A1 |
| 20090054842 | Yeshurun et al. | Feb 2009 | A1 |
| 20090099537 | DeVoe et al. | Apr 2009 | A1 |
| 20090326415 | Lim | Dec 2009 | A1 |
| 20100193997 | Frederickson et al. | Aug 2010 | A1 |
| 20100305516 | Xu et al. | Dec 2010 | A1 |
| 20110046556 | Kraft | Feb 2011 | A1 |
| 20110172605 | Berenschot et al. | Jul 2011 | A1 |
| 20110172609 | Moga et al. | Jul 2011 | A1 |
| 20110192562 | Motoi et al. | Aug 2011 | A1 |
| 20110213335 | Burton et al. | Sep 2011 | A1 |
| 20120041337 | Ferguson et al. | Feb 2012 | A1 |
| 20120123387 | Gonzalez et al. | May 2012 | A1 |
| 20120258284 | Rendon | Oct 2012 | A1 |
| 20140236075 | Sugimura | Aug 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 101244303 | Sep 2010 | CN |
| 101856538 | Oct 2010 | CN |
| 10 2008 052 749 | May 2010 | DE |
| 2 062 611 | May 2009 | EP |
| 2010-502267 | Jan 2010 | JP |
| 2013-116219 | Jun 2013 | JP |
| 10-2009-0025937 | Mar 2009 | KR |
| WO 2006025786 | Mar 2006 | WO |
| WO 2008027011 | Mar 2008 | WO |
| WO 2009130926 | Oct 2009 | WO |
| WO 2012074576 | Jun 2012 | WO |
| WO 2012122162 | Sep 2012 | WO |
| WO 2012126784 | Sep 2012 | WO |
| WO 2013061825 | May 2013 | WO |
| WO 2014099404 | Jun 2014 | WO |
| WO 2014105458 | Jul 2014 | WO |
| WO 015009524 | Jan 2015 | WO |
| WO 2015009530 | Jan 2015 | WO |
| WO 2015009531 | Jan 2015 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20160166819 A1 | Jun 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61846945 | Jul 2013 | US |
